San Carlos, CA, United States
San Carlos, CA, United States

Time filter

Source Type

Patent
Nektar Therapeutics | Date: 2016-04-22

The invention provides for preparing a polymer-active agent conjugate, the method comprising the steps of reacting an amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.


Patent
Nektar Therapeutics | Date: 2016-03-21

Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.


Patent
Astrazeneca and Nektar Therapeutics | Date: 2016-03-09

Naloxol-polyethylene glycol conjugates of the formula:


Patent
Nektar Therapeutics | Date: 2016-02-18

The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.


Patent
Nektar Therapeutics | Date: 2016-01-15

The invention relates to (among other things) methods for treatment comprising administering oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.


Patent
Nektar Therapeutics | Date: 2016-08-25

The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.


Patent
Nektar Therapeutics | Date: 2016-05-10

Apparatus (500) and components for coupling fluid or gas conducting elements, such as apparatus and components for connecting a nebulizer (501) with a gas flow system. In particular, the apparatus (500) and components are useful for connecting, in a gas-tight and quick release manner, a nebulizer (501) to a pressure-assisted breathing system, such as a mechanical ventilator or a continuous airway pressure (CPAP) system.


Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.


Patent
Nektar Therapeutics | Date: 2016-02-16

Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.


Patent
Nektar Therapeutics | Date: 2016-05-25

The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.

Loading Nektar Therapeutics collaborators
Loading Nektar Therapeutics collaborators